About Acadia Pharmaceuticals (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871
Debt
Debt-to-Equity RatioN/A
Current Ratio7.62%
Quick Ratio7.51%
Price-To-Earnings
Trailing P/E Ratio-8.33
Forward P/E Ratio-10.70
P/E GrowthN/A
Sales & Book Value
Annual Sales$124.90 million
Price / Sales19.44
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book7.21
Profitability
EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-231.71%
Return on Equity-73.02%
Return on Assets-65.87%
Miscellaneous
Employees425
Outstanding Shares124,700,000
Acadia Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is Acadia Pharmaceuticals' stock symbol?
Acadia Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were Acadia Pharmaceuticals' earnings last quarter?
Acadia Pharmaceuticals (NASDAQ:ACAD) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.03. The biopharmaceutical company had revenue of $43.56 million for the quarter, compared to the consensus estimate of $45.30 million. Acadia Pharmaceuticals had a negative net margin of 231.71% and a negative return on equity of 73.02%. View Acadia Pharmaceuticals' Earnings History.
When is Acadia Pharmaceuticals' next earnings date?
What price target have analysts set for ACAD?
12 brokers have issued 1-year price objectives for Acadia Pharmaceuticals' stock. Their forecasts range from $45.00 to $61.00. On average, they anticipate Acadia Pharmaceuticals' share price to reach $51.2727 in the next year. View Analyst Ratings for Acadia Pharmaceuticals.
What are Wall Street analysts saying about Acadia Pharmaceuticals stock?
Here are some recent quotes from research analysts about Acadia Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (1/24/2018)
- 2. HC Wainwright analysts commented, "HARMONY Study Initiation: Killing Multiple" Birds With One Stone? Reit Buy and $60 PT Initiation of the Ph3 HARMONY study is one step forward with our bull thesis. With the initiation of HARMONY study in dementia-related psychosis (DRP) and discontinuation of SEREN study in AD agitation, we applaud what we view as a smart move by Acadia of pursuing a broader indication for pimavanserin, and more importantly, doing so with a solid clinical plan moving forward. At first glance, the seemingly bold move into DRP from ADP may appear over-ambitious (killing multiple" birds with one stone). However, we note that a psychosis focus/approach may prove to be a smart play from both the commercial point of view and also from the mechanistic perspective. The blessing from the FDA with a Breakthrough Designation further elevates our sanguine outlook for the program. We highlight the significant upside coming with the DRP expansion as the target market is potentially bigger than ADP alone (if we assume ADP comprises 70% of the DRP)." (10/5/2017)
Who are some of Acadia Pharmaceuticals' key competitors?
Some companies that are related to Acadia Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM) and Taro Pharmaceutical Industries (TARO).
Who are Acadia Pharmaceuticals' key executives?
Acadia Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
- Mr. Todd S. Young, Exec. VP, CFO & Principal Accounting Officer (Age 46)
- Mr. Glenn F. Baity, Exec. VP, Gen. Counsel and Sec. (Age 48)
- Dr. Srdjan R. Stankovic M.D., M.S.P.H., Head of R&D and Exec. VP (Age 61)
- Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
Has Acadia Pharmaceuticals been receiving favorable news coverage?
Media headlines about ACAD stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acadia Pharmaceuticals earned a coverage optimism score of 0.03 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Acadia Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acadia Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $19.47.
How big of a company is Acadia Pharmaceuticals?
Acadia Pharmaceuticals has a market capitalization of $2.48 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. Acadia Pharmaceuticals employs 425 workers across the globe.
How can I contact Acadia Pharmaceuticals?
Acadia Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for Acadia Pharmaceuticals (ACAD)
MarketBeat's community ratings are surveys of what our community members think about Acadia Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Acadia Pharmaceuticals (NASDAQ:ACAD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Acadia Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.2727, suggesting that the stock has a possible upside of 163.34%. The high price target for ACAD is $61.00 and the low price target for ACAD is $45.00. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.83 | 2.83 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $51.2727 | $51.2727 | $51.2727 | $49.4167 |
| Price Target Upside: | 163.34% upside | 73.04% upside | 73.04% upside | 38.19% upside |
Acadia Pharmaceuticals (NASDAQ:ACAD) Consensus Price Target History
Acadia Pharmaceuticals (NASDAQ:ACAD) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Acadia Pharmaceuticals (NASDAQ:ACAD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Acadia Pharmaceuticals (NASDAQ ACAD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 96.17%
Acadia Pharmaceuticals (NASDAQ ACAD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Daniel B Soland | Director | Buy | 7,000 | $23.91 | $167,370.00 | 2,000 |  |
| 1/29/2018 | Glenn Baity | EVP | Sell | 36,558 | $32.39 | $1,184,113.62 | 83,734 | |
| 1/2/2018 | Glenn Baity | EVP | Sell | 74,321 | $30.14 | $2,240,034.94 | | |
| 1/2/2018 | Laura Brege | Director | Sell | 25,000 | $30.06 | $751,500.00 | 15,000 | |
| 10/5/2017 | Glenn Baity | EVP | Sell | 37,500 | $40.91 | $1,534,125.00 | | |
| 8/30/2017 | Glenn Baity | EVP | Sell | 26,507 | $34.87 | $924,299.09 | 94,163 | |
| 8/9/2017 | Glenn Baity | EVP | Sell | 14,322 | $34.88 | $499,551.36 | 78,578 | |
| 7/20/2017 | Glenn Baity | EVP | Sell | 38,097 | $30.00 | $1,142,910.00 | 109,253 | |
| 6/22/2017 | Glenn Baity | EVP | Sell | 1,903 | $30.00 | $57,090.00 | 83,059 | |
| 2/16/2017 | Terrence O. Moore | EVP | Sell | 157,540 | $39.77 | $6,265,365.80 | | |
| 12/27/2016 | Glenn Baity | EVP | Sell | 9,800 | $30.46 | $298,508.00 | 81,363 | |
| 12/20/2016 | Glenn Baity | EVP | Sell | 10,000 | $30.00 | $300,000.00 | | |
| 8/16/2016 | Edmund Harrigan | Director | Buy | 1,000 | $32.97 | $32,970.00 | 1,000 | |
| 8/10/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,303,030 | $33.00 | $42,999,990.00 | | |
| 7/12/2016 | Glenn Baity | EVP | Sell | 16,000 | $35.00 | $560,000.00 | 66,978 | |
| 7/11/2016 | Glenn Baity | EVP | Sell | 4,057 | $35.00 | $141,995.00 | 66,978 | |
| 4/18/2016 | Leslie L Iversen | Director | Sell | 33,697 | $33.53 | $1,129,860.41 | 69,824 | |
| 4/1/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,449,090 | $27.08 | $39,241,357.20 | | |
| 1/7/2016 | L.P. 14159 | Director | Buy | 2,586,206 | $29.00 | $74,999,974.00 | | |
| 11/11/2015 | Leslie L. Iversen | Director | Sell | 30,000 | $36.01 | $1,080,300.00 | 36,127 | |
| 1/15/2015 | Michael T Borer | Director | Sell | 27,973 | $33.02 | $923,668.46 | | |
| 1/14/2015 | Uli Hacksell | CEO | Sell | 30,000 | $33.98 | $1,019,400.00 | | |
| 12/15/2014 | Mary Ann Gray | Director | Sell | 12,250 | $31.74 | $388,815.00 | | |
| 12/15/2014 | Uli Hacksell | CEO | Sell | 30,000 | $31.00 | $930,000.00 | | |
| 11/26/2014 | Michael T Borer | Director | Sell | 15,000 | $30.05 | $450,750.00 | | |
| 11/26/2014 | Roger Mills | CMO | Sell | 25,000 | $30.09 | $752,250.00 | | |
| 11/24/2014 | Uli Hacksell | CEO | Sell | 30,000 | $29.28 | $878,400.00 | | |
| 11/21/2014 | William Mcdowall Wells | Director | Sell | 5,810 | $29.00 | $168,490.00 | | |
| 10/8/2014 | Uli Hacksell | CEO | Sell | 30,000 | $24.15 | $724,500.00 | | |
| 9/15/2014 | Laura Brege | Director | Sell | 10,000 | $28.07 | $280,700.00 | | |
| 9/12/2014 | William Mcdowall Wells | Director | Sell | 9,190 | $29.15 | $267,888.50 | | |
| 9/10/2014 | Uli Hacksell | CEO | Sell | 30,000 | $27.36 | $820,800.00 | | |
| 8/15/2014 | Uli Hacksell | CEO | Sell | 15,000 | $22.89 | $343,350.00 | | |
| 7/14/2014 | Uli Hacksell | CEO | Sell | 20,000 | $22.22 | $444,400.00 | | |
| 6/16/2014 | Uli Hacksell | CEO | Sell | 20,000 | $23.10 | $462,000.00 | | |
| 6/9/2014 | William Mcdowall Wells | Director | Sell | 15,000 | $23.03 | $345,450.00 | | |
| 5/1/2014 | Torsten Rasmussen | Director | Sell | 32,857 | $20.03 | $658,125.71 | | |
| 4/15/2014 | Uli Hacksell | CEO | Sell | 25,000 | $17.75 | $443,750.00 | | |
| 4/4/2014 | Thomas Aasen | CFO | Sell | 15,000 | $22.48 | $337,200.00 | 23,848 | |
| 4/4/2014 | Torsten Rasmussen | Director | Sell | 30,000 | $21.98 | $659,400.00 | | |
| 3/5/2014 | Bros. Advisors Lp Baker | Director | Buy | 526,316 | $28.50 | $15,000,006.00 | | |
| 2/26/2014 | Glenn Baity | VP | Sell | 42,000 | $30.28 | $1,271,760.00 | 47,788 | |
| 11/1/2013 | Torsten Rasmussen | Director | Sell | 37,692 | $23.00 | $866,916.00 | | |
| 11/1/2013 | Uli Hacksell | CEO | Sell | 15,000 | $23.24 | $348,600.00 | | |
| 10/10/2013 | Laura Brege | Director | Sell | 10,000 | $21.63 | $216,300.00 | | |
| 10/1/2013 | Thomas H Aasen | CFO | Sell | 30,000 | $27.87 | $836,100.00 | | |
| 9/20/2013 | Roger Mills | CMO | Sell | 35,965 | $25.01 | $899,484.65 | 15,775 | |
| 9/12/2013 | Lester Ph Kaplan | Director | Sell | 66,356 | $22.90 | $1,519,552.40 | 8,500 | |
| 9/10/2013 | Laura Brege | Director | Sell | 46,153 | $22.80 | $1,052,288.40 | | |
| 9/3/2013 | Torsten Rasmussen | Director | Sell | 40,000 | $20.28 | $811,200.00 | | |
| 8/26/2013 | Mary Ann Gray | Director | Sell | 15,000 | $20.68 | $310,200.00 | | |
| 8/13/2013 | Thomas Aasen | CFO | Sell | 60,000 | $20.15 | $1,209,000.00 | 31,585 | |
| 8/13/2013 | Uli Hacksell | CEO | Sell | 52,771 | $20.14 | $1,062,807.94 | | |
| 6/5/2013 | Felix Baker | Director | Buy | 2,340,314 | $14.34 | $33,560,102.76 | | |
| 5/15/2013 | Felix Baker | Director | Buy | 1,993,000 | $12.50 | $24,912,500.00 | | |
| 4/12/2013 | Glenn Baity | VP | Sell | 60,000 | $12.42 | $745,200.00 | | |
| 4/11/2013 | Thomas H Aasen | CFO | Sell | 40,000 | $11.06 | $442,400.00 | | |
(Data available from 1/1/2013 forward)
Acadia Pharmaceuticals (NASDAQ ACAD) News Headlines
| Source: |
|
Acadia Pharmaceuticals (NASDAQ:ACAD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Acadia Pharmaceuticals (NASDAQ:ACAD) Income Statement, Balance Sheet and Cash Flow Statement
Acadia Pharmaceuticals (NASDAQ ACAD) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
